Ursodiol protects the liver by replacing toxic bile acids with a gentler, nontoxic form that shields liver cells from damage. It’s one of the few medications proven to slow the progression of chronic liver disease, and in people with primary biliary cholangitis (PBC), it cuts the risk of needing a liver transplant nearly in half. Depending on the condition being treated, it can also dissolve certain gallstones and improve liver enzyme levels in as little as four weeks.
How Ursodiol Protects Liver Cells
Your liver produces bile acids to help digest fat, but some of these acids are harsh. They’re hydrophobic, meaning they repel water, and at high concentrations they can damage the membranes of liver cells and the cells lining your bile ducts. Ursodiol is a naturally occurring bile acid that’s hydrophilic, or water-friendly, making it far less corrosive to tissue.
When you take ursodiol regularly, it gradually shifts the balance of your bile acid pool. The nontoxic ursodiol molecules physically displace the more damaging bile acids from cell membranes, preventing the chemical injury those acids would otherwise cause. Over time, ursodiol and its breakdown products become the dominant bile acids circulating through your liver, essentially swapping out an irritating chemical environment for a milder one.
Ursodiol also strengthens a protective layer on the surface of bile duct cells known as the “bicarbonate umbrella.” Bile duct cells normally secrete bicarbonate to maintain an alkaline barrier that keeps bile acids in a less harmful state. In diseases like PBC, this barrier breaks down. Ursodiol boosts bicarbonate secretion, helping restore that protective shield and reducing ongoing damage to the bile ducts.
Primary Biliary Cholangitis
The best-studied use of ursodiol is in PBC, a chronic autoimmune condition where the immune system slowly destroys the small bile ducts inside the liver. Without treatment, bile backs up, damages liver tissue, and can eventually lead to cirrhosis and liver failure. Ursodiol is the first-line treatment for PBC and remains the only medication with decades of survival data behind it.
A large study of nearly 3,900 PBC patients found that 10-year transplant-free survival was about 80% in those treated with ursodiol, compared to roughly 61% in untreated patients. That translates to a 54% reduction in the risk of death or liver transplant. Importantly, this benefit held across all stages of the disease. Even patients whose blood tests didn’t fully normalize after a year of treatment still had significantly better outcomes than those who received no treatment at all.
For PBC, the typical dose is 13 to 15 milligrams per kilogram of body weight per day, split into two to four doses. Most people take it long-term, often for life.
Dissolving Gallstones
Ursodiol can dissolve cholesterol-based gallstones, though it works best on small ones. In one study, complete dissolution occurred in about 57% of patients after 12 months of treatment, compared to less than 1% of untreated patients. Stones smaller than 5 millimeters had the highest success rate. It doesn’t work on pigment stones or calcified stones, and larger stones are generally better treated with surgery.
For gallstone dissolution, the dose is lower than for PBC: typically 8 to 10 milligrams per kilogram per day. Ursodiol is also used preventively during rapid weight loss, such as after bariatric surgery, when the risk of developing new gallstones spikes. In that case, a standard prevention dose of 300 milligrams twice daily is common.
How Quickly It Works
You won’t feel ursodiol working the way you’d feel a painkiller, but its effects show up in blood tests relatively quickly. In one study, liver enzymes dropped substantially after just four weeks: ALT (a key marker of liver cell damage) fell by about 40%, AST dropped by 34%, and GGT decreased by 23%. A separate marker of liver injury, a small molecule called miR-122 that leaks from damaged liver cells, also began declining at the four-week mark.
For gallstone dissolution, patience is required. Most treatment courses run 6 to 12 months or longer, with periodic imaging to check progress. Stones don’t shrink overnight, and some never fully dissolve.
Cholestasis During Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a condition where bile flow slows during the third trimester, causing intense itching and raising bile acid levels in the blood. It’s associated with higher rates of preterm birth and, in severe cases, stillbirth. Ursodiol is commonly prescribed for ICP, though the evidence for its benefits is nuanced.
A large meta-analysis combining data from over 7,000 pregnancies found that ursodiol reduced spontaneous preterm birth, particularly in women with bile acid levels above 40 micromoles per liter (the higher-risk group). In randomized trials, treated women also had lower rates of the combined outcome of stillbirth plus preterm birth, and less meconium-stained amniotic fluid, a sign of fetal distress. However, the effect on stillbirth alone was not statistically significant, likely because stillbirth is rare enough that even large studies struggle to detect a difference. The overall picture supports using ursodiol in ICP, with the clearest benefits for reducing preterm delivery in more severe cases.
When Ursodiol Can Cause Harm
One important exception to ursodiol’s safety profile involves primary sclerosing cholangitis (PSC), a different bile duct disease from PBC. High-dose ursodiol (28 to 30 milligrams per kilogram per day) actually worsened outcomes in PSC patients, particularly those with early-stage disease. Patients on high doses developed more complications, including esophageal varices, than those on placebo. The likely explanation is that at very high doses, the small intestine can’t absorb all the ursodiol. Bacteria in the colon convert the excess into lithocholic acid, a compound that’s genuinely toxic to the liver and bile ducts, potentially causing inflammation and scarring. Because of this, high-dose ursodiol is not recommended for PSC.
Common Side Effects
At standard doses, ursodiol is generally well tolerated, but gastrointestinal symptoms are common. In clinical data, abdominal pain occurred in up to 43% of patients, diarrhea in up to 27%, constipation in up to 26%, nausea in up to 17%, and vomiting in up to 14%. These numbers come from clinical trials where patients reported every symptom, so the real-world experience is often milder, but digestive discomfort is the most frequent reason people struggle with the medication.
Hair thinning (alopecia) and skin rash occur in 1% to 10% of users. Unusual weight changes have been reported but are rare and not well quantified. Most people find that side effects are manageable, especially when ursodiol is taken with food.